CTLT (Catalent) Change In Receivables : $92 Mil (TTM As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Catalent Change In Receivables?

Catalent's change in receivables for the quarter that ended in Sep. 2024 was $173 Mil. It means Catalent's Accounts Receivable declined by $173 Mil from Jun. 2024 to Sep. 2024 .

Catalent's change in receivables for the fiscal year that ended in Jun. 2024 was $79 Mil. It means Catalent's Accounts Receivable declined by $79 Mil from Jun. 2023 to Jun. 2024 .

Catalent's Accounts Receivable for the quarter that ended in Sep. 2024 was $760 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Catalent's Days Sales Outstanding for the three months ended in Sep. 2024 was 67.79.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Catalent's liquidation value for the three months ended in Sep. 2024 was $-4,970 Mil.

Catalent Change In Receivables Historical Data

The historical data trend for Catalent's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalent Change In Receivables Chart

Catalent Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Change In Receivables

Get a 7-Day Free Trial

-151.00

-186.00

-73.00

53.00

79.00

Catalent Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial															160.00	5.00	-35.00	-51.00	173.00

Catalent Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $92 Mil.

Catalent (NYSE:CTLT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Catalent's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	760	/	1023	*	91
=	67.79

2. In Ben Graham's calculation of liquidation value, Catalent's accounts receivable are only considered to be worth 75% of book value:

Catalent's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	335	-	6166	+	0.75 * 760	+	0.5 * 583
=	-4,970

Catalent Change In Receivables Related Terms

Thank you for viewing the detailed overview of Catalent's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalent Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Catalent Inc (NYSE:CTLT) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

14 Schoolhouse Road, Somerset, NJ, USA, 08873

Website

https://www.catalent.com

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

Executives

Michelle R Ryan	director	214 PARK BLVD S, VENICE FL 34285
Joseph Anthony Ferraro	officer: SVP, General Counsel, CCO	56 EMILY ROAD, FAR HILLS FL 07931
David Mcerlane	officer: Group President, Biologics	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Ricky Hopson	officer: VP, Chief Accounting Officer	CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Lisa Evoli	officer: SVP, Chief HR Officer	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Aristippos Gennadios	officer: See Remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Scott Gunther	officer: See Remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Alessandro Maselli	officer: See remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Matti Masanovich	officer: SVP, Chief Financial Officer	COLLINS & AIKMAN CORPORATION, 250 STEPHENSON HIGHWAY, TROY MI 48083
Steven Barg	director	ELLIOTT MANAGEMENT CORPORATION, 40 WEST 57TH STREET, NEW YORK NY 10019
John J Greisch	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Frank A Damelio	director	C/O PFIZER INC., 235 EAST 42ND ST., NEW YORK NY 10017
Stephanie Okey	director	C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109
Jonathan Arnold	officer: President, Oral Drug Delivery	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Steven L Fasman	officer: See Remarks	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873